2017
Adjuvant radiotherapy is not supported in patients with verrucous carcinoma of the oral cavity
Mohan S, Pai S, Bhattacharyya N. Adjuvant radiotherapy is not supported in patients with verrucous carcinoma of the oral cavity. The Laryngoscope 2017, 127: 1334-1338. PMID: 28150306, PMCID: PMC7388729, DOI: 10.1002/lary.26443.Peer-Reviewed Original ResearchMeSH KeywordsAgedCarcinoma, Squamous CellCarcinoma, VerrucousCross-Sectional StudiesDisease-Free SurvivalFemaleHead and Neck NeoplasmsHumansKaplan-Meier EstimateMaleMiddle AgedMouthMouth NeoplasmsNeoplasm Recurrence, LocalRadiotherapy, AdjuvantSEER ProgramSquamous Cell Carcinoma of Head and NeckTreatment OutcomeConceptsAdjuvant radiation therapyDisease-specific survivalSquamous cell carcinomaVerrucous carcinomaRadiation therapyOverall survivalOral cavityVC patientsWorse OSCarcinoma patientsImproved overall survivalEnd Results (SEER) databaseKaplan-Meier survivalAdjuvant radiotherapySCC patientsLocal recurrenceResults databaseT stagePositive marginsSCC casesCell carcinomaPatientsSurgeryCarcinomaDifferent biology
2016
SMAC Mimetic Birinapant plus Radiation Eradicates Human Head and Neck Cancers with Genomic Amplifications of Cell Death Genes FADD and BIRC2
Eytan D, Snow G, Carlson S, Derakhshan A, Saleh A, Schiltz S, Cheng H, Mohan S, Cornelius S, Coupar J, Sowers A, Hernandez L, Mitchell J, Annunziata C, Chen Z, Van Waes C. SMAC Mimetic Birinapant plus Radiation Eradicates Human Head and Neck Cancers with Genomic Amplifications of Cell Death Genes FADD and BIRC2. Cancer Research 2016, 76: 5442-5454. PMID: 27469115, PMCID: PMC5026594, DOI: 10.1158/0008-5472.can-15-3317.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntineoplastic AgentsBlotting, WesternCarcinoma, Squamous CellCell Line, TumorChemoradiotherapyDipeptidesFas-Associated Death Domain ProteinFemaleGene AmplificationGene Knockdown TechniquesHead and Neck NeoplasmsHumansImmunohistochemistryIndolesInhibitor of Apoptosis ProteinsMiceMice, Inbred BALB CMice, SCIDReal-Time Polymerase Chain ReactionSquamous Cell Carcinoma of Head and NeckTNF-Related Apoptosis-Inducing LigandTumor Necrosis Factor-alphaUbiquitin-Protein LigasesXenograft Model Antitumor AssaysConceptsSmac mimeticsCell deathNovel Smac mimeticsCaspase-dependent apoptosisExpression of FADDFrequent genomic amplificationCell cycle arrestBaculovirus inhibitorG2-M cell cycle arrestApoptosis repeatCancer Genome AtlasDeath domainIAP inhibitorsFunctional importanceSiRNA knockdownDNA fragmentationHNSCC cell linesFADDBirinapantGenomic amplificationGene transferGenome AtlasProtein markersComparison of tumorGenomic alterations
2015
MEK Inhibitor PD-0325901 Overcomes Resistance to PI3K/mTOR Inhibitor PF-5212384 and Potentiates Antitumor Effects in Human Head and Neck Squamous Cell Carcinoma
Mohan S, Vander Broek R, Shah S, Eytan D, Pierce M, Carlson S, Coupar J, Zhang J, Cheng H, Chen Z, Van Waes C. MEK Inhibitor PD-0325901 Overcomes Resistance to PI3K/mTOR Inhibitor PF-5212384 and Potentiates Antitumor Effects in Human Head and Neck Squamous Cell Carcinoma. Clinical Cancer Research 2015, 21: 3946-3956. PMID: 25977343, PMCID: PMC4558307, DOI: 10.1158/1078-0432.ccr-14-3377.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntineoplastic AgentsBenzamidesCarcinoma, Squamous CellCell Line, TumorCell ProliferationCell SurvivalCell Transformation, NeoplasticCytokinesDiphenylamineDisease Models, AnimalDrug Resistance, NeoplasmDrug SynergismGene ExpressionGenes, ReporterHead and Neck NeoplasmsHumansInflammation MediatorsMitogen-Activated Protein Kinase KinasesMorpholinesNF-kappa BPhosphatidylinositol 3-KinasesPhosphoinositide-3 Kinase InhibitorsPhosphorylationProtein Kinase InhibitorsSignal TransductionSquamous Cell Carcinoma of Head and NeckTOR Serine-Threonine KinasesTranscription Factor AP-1Transcriptional ActivationTriazinesXenograft Model Antitumor AssaysMEK Inhibitor PD-0325901 Overcomes Resistance to CK2 Inhibitor CX-4945 and Exhibits Anti-Tumor Activity in Head and Neck Cancer
Bian Y, Han J, Kannabiran V, Mohan S, Cheng H, Friedman J, Zhang L, VanWaes C, Chen Z. MEK Inhibitor PD-0325901 Overcomes Resistance to CK2 Inhibitor CX-4945 and Exhibits Anti-Tumor Activity in Head and Neck Cancer. International Journal Of Biological Sciences 2015, 11: 411-422. PMID: 25798061, PMCID: PMC4366640, DOI: 10.7150/ijbs.10745.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsBenzamidesBlotting, WesternCasein Kinase IICell Line, TumorDiphenylamineFemaleFlow CytometryHead and Neck NeoplasmsHumansJNK Mitogen-Activated Protein KinasesMiceMice, Inbred BALB CMice, SCIDNaphthyridinesNF-kappa BPhenazinesProto-Oncogene Proteins c-fosTumor Suppressor Protein p53Xenograft Model Antitumor AssaysConceptsAnti-tumor activityMEK inhibitor PD-0325901PD-901CK2 inhibitor CXModest anti-tumor activityNeck squamous cell carcinomaPD-0325901Cell linesSignificant anti-tumor effectHuman HNSCC cell linesUM-SCC cell linesP-AKT T308Squamous cell carcinomaIL-8 activityFurther clinical investigationAnti-tumor effectsHNSCC cell linesDNA flow cytometryAP-1 pathwayDrug resistance mechanismsExhibit anti-tumor activityResistance mechanismsUM-SCC1Cell carcinomaNeck cancer
2013
The PI3K/Akt/mTOR axis in head and neck cancer: functions, aberrations, cross‐talk, and therapies
Broek R, Mohan S, Eytan D, Chen Z, Van Waes C. The PI3K/Akt/mTOR axis in head and neck cancer: functions, aberrations, cross‐talk, and therapies. Oral Diseases 2013, 21: 815-825. PMID: 24219320, DOI: 10.1111/odi.12206.Peer-Reviewed Original ResearchConceptsAkt/mTOR axisPI3K/Akt/mTOR axisDNA copy number variationsMTOR axisCopy number variationsPI3K/Akt/mTORDysregulation of mRNAsNeck squamous cell carcinomaPI3K/AKT/mTOR pathwayAKT/mTOR pathwayAkt/mTORSquamous cell carcinomaPathway leadCell survivalNumber variationsPI3KMalignant phenotypeMTOR pathwayNormal physiologyCell carcinomaHNSCC casesNeck cancerClinical studiesProtein expressionGenetic aberrations